PMOS Health Risks Extend Beyond Menopause
A 2026 review by UCSF doctors finds Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a lifelong condition. While some reproductive symptoms ease with age, the risks for heart disease, metabolic problems, and psychological issues persist long after menopause.
Polyendocrine Metabolic Ovarian Syndrome (PMOS) remains a significant health threat for women long after their reproductive years end. A 2026 narrative review by Dr. Elena HogenEsch and Dr. Heather G. Huddleston of the University of California, San Francisco, argues the condition requires lifelong monitoring and care.
While the classic reproductive symptoms of PMOS often improve as women age, this does not mean the underlying disorder is resolved. The review states that diagnosing PMOS in women in their 30s and 40s can be challenging precisely because of these favorable changes.
Symptom Evolution With Age
Menstrual cycles often become more regular. Ovulatory function improves. The appearance of the ovaries on ultrasound normalizes. Biochemical signs of high male hormones, or hyperandrogenism, also tend to lessen. These shifts can mask the ongoing presence of PMOS, leading to a false sense of security for patients and clinicians alike.
The authors caution that this symptomatic relief is misleading. Emerging evidence clearly shows the metabolic dysfunction at the core of PMOS does not disappear. It continues to pose serious long-term health risks.
Lifelong Cardiometabolic Risks
The increased burden of metabolic problems and cardiovascular disease follows women with PMOS into midlife and beyond. The disorder is linked to a higher lifetime risk of developing type 2 diabetes, high blood pressure, and unhealthy cholesterol levels. These factors collectively raise the chance of experiencing heart attacks, strokes, and other major cardiovascular events later in life.
This persistent risk profile shows the need for continuous health surveillance. Women with a history of PMOS require proactive, preventive care focused on metabolic health long after concerns about fertility have passed.
Psychological and Cognitive Concerns
Beyond physical health, the review highlights ongoing psychological comorbidity. Women with PMOS face a higher likelihood of dealing with anxiety, depression, and other mood disorders throughout their lives. Some studies also suggest a potential link between PMOS and an increased risk for cognitive decline, including conditions like dementia, though more research is needed in this area.
The psychological impact is a critical component of the syndrome that demands attention and integrated care strategies at every life stage.
Gaps in Research and Future Directions
Dr. HogenEsch and Dr. Huddleston point out significant limitations in the current scientific literature. There is a relative shortage of long-term studies that track women with PMOS well past menopause. This gap makes it difficult to fully quantify the risks in older age groups.
Priorities for future research include more longitudinal studies and a clearer understanding of how to best diagnose and manage PMOS in perimenopausal and postmenopausal women. The authors conclude that recognizing PMOS as a lifelong endocrine disorder is essential for proper risk assessment and multidisciplinary management across a woman's entire lifespan.
